3 results
Primary Safety Objective * Proportion of patients who complete 24 weeks of combination treatment on pirfenidone at a dose of 1602*2403 mg/d and nintedanib at a dose of 200*300 mg/d Secondary Safety Objective * Proportion of patients who discontinue…
1) To evaluate the efficacy of knee-ankle-foot orthoses (worn by night) in preventing a decrease of range of motion to ankle dorsiflexion in children with cerebral palsy (Clinical part). 2) To evaluate the effect of night-worn knee-ankle-foot…
Phase Ia: (dose escalation):- To determine the maximum tolerated dose (MTD) and a recommended Phase II dose (RP2D) for M3814 (also referred to as MSC2490484A) in combination with fractionated palliative radiotherapy (RT) for tumors or metastases…